Community Practice Connections™: Bladder Cancer Working Group: Practical Application of Immunotherapeutic Strategies to Optimize Patient Outcomes, Next Steps to Move the Field Forward

Community Practice Connections™: Bladder Cancer Working Group: Practical Application of Immunotherapeutic Strategies to Optimize Patient Outcomes, Next Steps to Move the Field Forward is organized by Physicians' Education Resource, LLC (PER).

Release Date: July 31, 2019
Expiration Date: July 31, 2020

Target Audience:
This educational program is directed toward urologists, oncologists, and researchers involved in the treatment of patients with bladder cancers. Nurse practitioners, physician assistants, nurses, and other healthcare professionals interested in the treatment and management of patients with bladder cancers are also invited to participate.

Accreditation/Credit Designation:
Physicians' Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians' Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 1.5 Contact Hours.

Activity Overview:
Now, even while clinicians are sorting through data from clinical studies of single-agent immunotherapy for advanced/metastatic urothelial cancer (UC), the field is poised to pivot again as a multitude of ongoing clinical studies are evaluating single-agent and combination immunotherapy (IO) strategies across all stages of bladder cancer. Additionally, novel agents are being studied to address the unmet needs of patients with UC that is refractory to immune checkpoint inhibitor therapy. Use of these agents across multiple lines of therapy for advanced UC and the potential expansion of their use to early-stage disease makes it imperative that urologists, as the primary care providers for patients with early-stage disease and the gatekeepers for referral to other specialists, understand both new data and best practices related to the use of IO, including proactively monitoring, mitigating, and managing immune-related adverse events. This interactive, online activity is based on a live symposium held adjunct to the 2019 annual urology meeting in Chicago. Through a series of brief video interviews, the multidisciplinary faculty—comprising renowned experts in urology, medical oncology, and IO—review practice-changing data and its impact on patient care, discuss “real-world” clinical cases, and share forward-looking perspectives on the bladder cancer treatment horizon.

Learning Objectives:
Upon successful completion of this educational activity, you should be better prepared to:
• Identify the rationale for using immunotherapy (IO)-based approaches to treat bladder cancer
• Analyze key data from clinical trials of IO and other emerging agents for bladder cancer
• Consider practice-changing evidence from clinical trials of IO, cytotoxic agents, and targeted therapies during multidisciplinary, team-based care planning for patients with bladder cancer
• Outline immune-related adverse events and best practices for their mitigation and management.